Bioaegis Therapeuticsincis A Clinical Stage Biotechnology Company Based In New Jerseythe Company Focuses On Developing Therapies For Infectiousinflammatoryand Degenerative Diseases By Targeting The Regulation Of The Innate Immune Systembioaegis Utilizes Plasma Gelsolinpgsn A Naturally Occurring Human Proteinto Address Systemic Inflammation And Immune Dysregulation In Severe Conditions The Company S Lead Product Is A Recombinant Human Plasma Gelsolin Replacement Therapy Currently In Phase 2 Trials For Acute Respiratory Distress Syndromeards This Therapy Aims To Restore Depleted Pgsn Levelsacting As A Master Regulator Of Inflammation And Enhancing Antimicrobial Defensebioaegis Is Also Developing Additional Candidates For Conditions Such As Community Acquired Pneumoniatraumaburnsand Sepsisthe Company Employs Biomarker Directed Strategies To Identify Patients Who Are Most Likely To Benefit From Its Therapiesemphasizing The Modulation Of Innate Immunity Without Causing Immunosuppression
